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Abstract
Background: There are hardly any data about the incidence, risk factors and outcomes of ICU-associated A.baumannii
colonisation/infection in HIV-infected and uninfected persons from resource-poor settings like Africa.
Methods: We reviewed the case records of patients with A.baumannii colonisation/infection admitted into the adult
respiratory and surgical ICUs in Cape Town, South Africa, from January 1 to December 31 2008. In contrast to colonisation,
infection was defined as isolation of A.baumannii from any biological site in conjunction with a compatible clinical picture
warranting treatment with antibiotics effective against A.baumannii.
Results: The incidence of A.baumannii colonisation/infection in 268 patients was 15 per 100 person-years, with an in-ICU
mortality of 26.5 per 100 person-years. The average length of stay in ICU was 15 days (range 1–150). A.baumannii was most
commonly isolated from the respiratory tract followed by the bloodstream. Independent predictors of mortality included
older age (p = 0.02), low CD4 count if HIV-infected (p = 0.038), surgical intervention (p = 0.047), co-morbid Gram-negative
sepsis (p = 0.01), high APACHE-II score (p = 0.001), multi-organ dysfunction syndrome (p = 0.012), and a positive blood
culture for A.baumannii (p = 0.017). Of 21 A.baumannii colonised/infected HIV-positive persons those with clinical AIDS
(CD4,200 cells/mm3) had significantly higher in-ICU mortality and were more likely to have a positive blood
culture. Conclusion In this resource-poor setting A.baumannii infection in critically ill patients is common and associated
with high mortality. HIV co-infected patients with advanced immunosuppression are at higher risk of death.
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Introduction
Traditionally, Acinetobacter baumannii has been considered to be
an opportunistic pathogen of low pathogenicity [1], but the
emergence of serious community-acquired A.baumannii infection
has demonstrated that this organism can be highly virulent with
a propensity to cause invasive disease in non-critically ill patients.
[2] Nosocomial transmission is responsible for the vast majority of
A.baumannii infections, [3] and is related both to the ability of the
organism to survive in the environment and the organism’s
resistance to the major groups of antibiotics, resulting in a selective
advantage in settings such as ICUs, where broad-spectrum
antibiotic use is commonplace. The incidence of nosocomial
infections due to Gram negative infections in South Africa has
previously been reported to be between 24 and 36%. [4,5] When
A.baumannii is isolated from patient-derived biological samples
distinction is often made between colonisation and active infection
(associated features of sepsis and/or a positive blood culture). [6]
Globally, there has been a general trend of increasing incidence of
infection due to A.baumannii. [7] For instance, in France
nosocomial infection due to A.baumannii was rare in the 1970s
and had increased to a prevalence of 9% by 2005. [8] Similarly, in
North America, the prevalence of nosocomial infection due to
A.baumannii increased from 4% in 1986 to 7% in 2003. [9] Patients
at risk are often critically ill with multiple co-morbidities,
concurrent infections, and on prolonged courses of antibiotics,
often making it difficult to distinguish between colonisation and
infection. [10] Moreover, colonisation is a risk factor for sub-
sequent infection [6].
Rational planning of health care policy and interventional
measures are required to tackle ICU-associated A.baumannii
infection in resource-poor settings. However, there are inadequate
data on which to plan interventional strategies and base
recommendations. Firstly, the frequency, risk factors and associ-
ated mortality of A.baumannii in African ICUs have not been
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determined. Thus, apart from a brief report describing the
molecular epidemiology of A.baumannii [11] and the comparative
efficacy of different antimicrobials [12] there is a paucity of data
about A.baumannii from the African continent and other resource-
poor settings. Secondly, the incidence, risk factors and prognosis of
HIV-infected persons with A.baumannii requires clarification; such
data have important implications for management of patients from
high HIV prevalence settings. We hypothesised that, in contrast to
developed countries, in resource-poor settings like South Africa
A.baumannii colonisation/infection is less common but associated
with altered outcomes in HIV-infected persons. The UNAIDS
estimates that the prevalence of HIV infection in South Africa is
18%, [13] however the prevalence of HIV infected persons in
adult ICUs in the country is generally much lower.
To address these questions we reviewed the case records of all
patients with A.baumannii infection/colonisation admitted to the
adult ICUs at Groote Schuur hospital (GSH) in Cape Town,
South Africa. Cape Town has a population of ,3.5 million
people. GSH is a 900-bed, government-funded hospital providing
tertiary care in all the major branches of medicine, and is the chief
academic teaching hospital of the University of Cape Town. GSH
employs 500 doctors, 1300 nurses and 250 allied health
professionals. The public sector, within which GSH is situated,
is over-subscribed and under-resourced, as it is constantly under
pressure to deliver healthcare services to over 80% of the
population, and faces the serious challenges of prevalent HIV/
AIDS, poverty and shortage of medical personnel. The specific
study aims were to (i) describe the incidence and site from which
A.baumannii was isolated in an adult ICU population, (ii) determine
the outcomes of patients with A.baumannii colonisation vs. infection,
(iii) determine the risk factors associated with poor outcome in this
subgroup of patients, and (iv) determine the epidemiology and




The study was designed as a retrospective cohort review of
patients admitted into the adult ICUs at GSH.
Study Population and Definitions
Patients from whom A.baumannii was isolated from any
biological sample, from 1 January 2008 to 31 December 2008
following admission to one of the adult respiratory or surgical
ICUs at GSH, were included in the study. The patients were
identified from the National Health Laboratory System (NHLS)
and the pharmacy computer records based on positive A.baumannii
microbiology and/or treatment for A.baumannii.
A.baumannii infection was defined as any patient who had
A.baumannii isolated from any site in conjunction with a compatible
clinical picture warranting treatment with antibiotics effective
against A.baumannii. The decision to treat was taken by the
attending lead physician based on clinical signs and laboratory
parameters indicating systemic inflammatory response/sepsis.
Active infection cases were divided into definite (isolation from
the bloodstream) or probable cases (isolation from another site, e.g.
respiratory tract). Colonisation was defined as isolation of the
organism with no antibiotic therapy as it was deemed by the
attending physician not to be clinically significant.
This study was approved by the University of Cape Town
Research Ethics Committee. However, written informed consent
was not obtained from patients for the information to be stored
into a hospital database and to be utilised for research as this is
a retrospective study and the data was collected after patients had
been discharged from the hospital. This conduct was approved by
the Research Ethics Committee.
Measurements and Data Collection
A comprehensive data collection database that incorporated
patient demographic details, medical history and co-morbidity, as
well as details of ICU stay and management was utilised. The
specific patient-related risk factors that were explored included
HIV status, co-morbid disease, presence of C-reactive protein
(CRP), serum albumin and increased white cell count. The
treatment-related factors that were explored included prior and
current antibiotic use and choice, use of mechanical ventilation,
and instrumentation during the ICU admission. Factors related to
the route of entry to ICU and management before the index ICU
admission were considered. The specific outcome measures
evaluated included death in the ICU, length of ICU admission,
duration of antibiotic treatment in ICU (colistin, meropenem or
aminoglycoside), cure in those with infection, and colonisation.
Statistical Analysis
Pearson’s chi-square or Fisher’s exact test were used to compare
the relative frequency of characteristics between the two groups of
patients. Cox’s binary logistical regression analysis was used for
determining independent predictors of mortality in patients
infected/colonised with A.baumannii in the adult ICUs.
Results
Incidence of A.baumannii Colonisation/infection in the
Adult ICUs
268 patients with positive A.baumannii cultures were identified in
the adult ICUs at GSH in 2008. In the same year, 1784 patients
were admitted to the ICU, giving an incidence of A.baumannii
colonisation/infection of 15 per 100 person-years. Of the 268
patients diagnosed with A.baumannii during the study period, 17
had either missing folders or incomplete information, and were
consequently excluded from the analysis. A sensitivity analysis
indicated that the demographic profile and HIV status of these 17
patients was similar to that of the 251 patients analysed and thus
unlikely to have biased the analysis.
ICU Mortality Associated with Microbiological Isolation of
A.baumannii
71 patients with A.baumannii infection died during their
admission into the ICU in this study. The ICU mortality
associated with A.baumannii was 26.5 per 100 person-years. In
the same year, the overall ICU mortality at GSH was 14.7 per 100
person-years. In-hospital mortality (before or after ICU) and 30-
day mortality were not recorded.
Demographic, Clinical and Laboratory Features and Risk
Factors for Acinetobacter Colonisation/infection in
Patients Admitted to Adult ICUs
Of 251 patients included in the analysis, 213 (84.9%) had
A.baumannii infection and 38 (15.1%) had A.baumannii colonisation.
Of the 213 patients with Acinetobacter infection, 91 (42.7%) had
definite infection, and the remaining 122 (57.3%) had probable
infection. Among patients who had A.baumannii isolated, risk
factors for developing colonisation instead of infection included
prior ICU admission (2.3 vs. 28.9%, p,0.001), invasive ventilation
in that ICU admission (20 vs. 90.9%, p,0.001), admission to the
trauma unit before current ICU admission (26.8 vs. 63.2%,
Acinetobacter baumannii Infection in HIV
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p= 0.003) and endotracheal tube (ETT) insertion in the trauma
unit (19.7 vs. 47.4%, p,0.001); (Table 1). Risk factors for
A.baumannii infection included recent surgery in the current
hospital admission (28.2 vs. 7.9%, p= 0.001), and ETT insertion
either in surgical theatre (29.6 vs. 2.6%, p,0.001); (Table 1).
Site of A.baumannii Isolation in ICU Patients
The respiratory tract was the most common site of isolation of
A.baumannii, accounting for 135 (53.8%) of all patients analysed,
and 24 (63.2%) of the patients meeting the case definition for
A.baumannii colonisation. Of those with respiratory tract A.bau-
mannii isolation, 98 (72%) had ventilator-associated pneumonia.
The majority of patients with Acinetobacter respiratory colonisation/
infection were discharged from ICU alive. 91 patients had
A.baumannii isolated from the blood, accounting for 65% of the
patients who demised in ICU, as shown in Table 2. Colonisation/
infection in the urine and wound sites was less common, and
accounted for 8.4% off all A.baumannii isolates, and 34.2% of
A.baumannii colonisation in the patients studied.
Antibiotic Susceptibility Patterns of A.baumannii Isolated
from Patients Admitted to Adult ICUs
The antibiotic susceptibility patterns are shown on Table 3.
High rates of resistance to cotrimoxazole, ciprofloxacin, merope-
nem, ceftazidime, cefepime, gentamycin, amikacin and pipericil-
lin-tazobactam were noted. Colistin remained the most effective
drug for treatment of multidrug-resistant A.baumannii, as 97.3% of
strains were susceptible to it. However, in this study, there were 2
patients with Acinetobacter infection that were resistant to all
Table 1. Demographic characteristics and risk factors for Acinetobacter baumannii in patients with infection vs. colonisation






Age in years, mean 6 SD 41.64616.05 41.33618.23 0.485
Male 146 (68.6) 24 (63.2) 0.327
HIV positive 20 (9.4) 1 (2.6) 0.201
For HIV infected: CD4 count, median (range) 221 (69–606) 130 0.009
Prior ICU admission, n (%) 5 (2.3) 11 (28.9) ,0.001
Ventilated in prior ICU admission, n (%) 1 (20) 10 (90.9) ,0.001
Ward before coming to ICU, n (%) 0.003
Medical A&E 26 (12.2) 3 (7.9) 0.003
Trauma Unit 57 (26.8) 24 (63.2) 0.003
Surgical wards 74 (34.7) 5 (13.2) 0.003
Medical wards 12 (5.6) 0 (0) 0.003
Gynaecology-Obstetrics wards 3 (1.4) 0 (0) 0.003
Secondary hospital ICU 36 (16.9) 5 (13.2) 0.003
Private hospital ICU 2 (0.9) 0 (0) 0.003
TBH ICU 3 (1.4) 1 (2.6) 0.003
Place of ETT insertion, n (%) ,0.001
Medical A&E 13 (6.1) 2 (5.3) ,0.001
Trauma Unit 42 (19.7) 18 (47.4) ,0.001
Surgical wards 3 (1.4) 9 (23.7) ,0.001
Medical wards 0 (0) 1 (2.6) ,0.001
Adult ICU 39 (18.3) 6 (15.8) ,0.001
Surgical theatre 63 (29.6) 1 (2.6) ,0.001
Secondary hospital ICU 34 (16) 0 (0) ,0.001
Private ICU 1 (0.5) 0 (0) ,0.001
No ETT in this admission 18 (8.4) 1 (2.6) ,0.001
Recent surgery in this admission, n (%) 60 (28.2) 3 (7.9) 0.001
Season during admission to ICU, n (%) 0.128
Summer 69 (32.4) 14 (36.8) 0.128
Autumn 49 (23) 7 (18.4) 0.128
Winter 52 (24.4) 6 (15.8) 0.128
Spring 43 (20.2) 11 (28.9) 0.128
Admitted to hospital in the last six months before this ICU admission, n (%) 45 (21.1) 8 (21.1) 0.505
MAE in ICU, n (%) 167 (78.4) 2 (5.3) ,0.001
HIV = human immunodeficiency virus, CD4= cluster of differentiation 4, ICU= intensive care unit, TBH= Tygerberg Hospital, ETT = endotracheal tube.
doi:10.1371/journal.pone.0052452.t001
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antibiotics, including colistin. Use of carbapenems (p = 0.043) and
aminoglycosides (p = 0.003) before the ICU admission were
associated with higher ICU mortality in those with A.baumannii
infection. Isolation of multidrug-resistant A.baumannii (resistant to
at least 3 classes of antibiotics) was associated with increased
mortality (p = 0.004). There were significantly higher proportions
of patients receiving colistin (59.2 vs. 24.4%, p= 0.008),
a carbapenem (49.3 vs. 25%, p,0.001) and/or an aminoglycoside
(28.2 vs. 15%, p= 0.020) to treat infection in the group of patients
who died in the ICU. In the group of 38 patients who were merely
colonised with A.baumannii, and did not receive antibiotics in the
ICU, there were no deaths (p = 0.004) compared to those with
infection; (Tables S1 and S2).
Length of Hospital Stay and Duration of Antibiotic
Treatment for Patients with A.baumannii Colonisation/
infection Admitted to Adult ICUs
The patients who achieved cure had a median pre-ICU hospital
stay of 2 days, and received antibiotics, usually given on an empiric
basis, before admission to ICU, for a median of 2 days. The
patients who died in ICU had a longer median pre-ICU hospital
admission of 10 days (p,0.001) compared to those who achieved
cure, and were also treated with antibiotics for longer before going
to ICU [median 10 days (p,0.001)]. The median length of ICU
stay was 9 days and 10 days for those who achieved cure and for
those who died in ICU, respectively (p = 0.471). The median
duration of ICU antibiotics was 7 days for both those who
achieved cure and those who demised in ICU (p= 0.802); (Table
S3).
Risk Factors for Mortality in Patients with A.baumannii
Infection Admitted to Adult ICUs
Patients who died from A.baumannii infection, when compared to
those who survived, were more likely to be older (46 years vs. 38
years; p = 0.001), female (45.1% vs. 27.2%; p= 0.005), and HIV-
infected (16.9% vs. 5.0%; p= 0.008); (Table S3). Dialysis, use of
inotropes (for septic shock), development of multi-organ dysfunc-
tion syndrome [MODS] and cardiorespiratory arrest were more
commonly associated with increased mortality in the ICU
(p,0.001).
Independent Predictors of Mortality in those with
A.baumannii Colonisation/infection in the ICU
The risk factors for mortality from A.baumannii in those with
HIV infection and in those with low CD4 counts are presented in
Tables S4 and S5. Multivariate logistic regression analysis revealed
that the independent predictors of mortality from A.baumannii
infection were: older age (p= 0.023), low CD4 count if HIV
positive (p = 0.038), surgery in the index admission (p = 0.047),
Gram negative other than A.baumannii (p = 0.014), a higher
APACHE II score (p = 0.001); MODS after A.baumannii infection
(p = 0.012), and a positive blood culture result for A.baumannii
(p = 0.017); (Table 4).
HIV and A.baumannii Colonisation/infection
Of the 251 patients included in the analysis, 183 patients were
HIV-uninfected, 47 patients’ HIV status was unknown and 21
patients were HIV-infected. When comparing the HIV infected to
the uninfected patients, the predictors of Acinetobacter colonisation/
infection included younger age (p= 0.042), female gender
(p = 0.028), CD4 count below 200 cells/ml (p = 0.037), an
APACHE II score greater than 30 (p = 0.010), and MODS
(p= 0.032); (Table 5). As shown in Table 6, on multivariate logistic
regression analysis, the specific predictors of mortality in HIV
patients with CD4 counts below 200 cells/ml (compared to those











colonization (N=38) P value
Blood only (%) 15 (8.3) 33 (46.5) 48 (22.5) 0 (0) 0.021
TA/BAL and blood (%) 40 (22.2) 18 (25.4) 57 (26.7) 1 (2.6) 0.108
TA/BAL only (%) 108 (60) 12 (16.9) 96 (45.1) 24 (63.2) 0.002
Urine and blood (%) 2 (1.1) 2 (2.8) 4 (1.9) 0 (0) 0.469
Urine only (%) 0 (0) 0 (0) 0 (0) 0 (0) N/A
Wound/abscess and blood (%) 7 (3.9) 6 (8.5) 8 (3.8) 0 (0) 0.078
Wound/abscess only (%) 8 (4.4) 0 (0) 0 (0) 13 (34.2) 0.179
TA= tracheal aspirate, BAL = broncheo-alveolar lavage. P value refers to comparison of patients with active A.baumannii discharged alive from ICU vs. those who died in
ICU. Wound/abscess sites include intra-abdominal swabs.
doi:10.1371/journal.pone.0052452.t002
Table 3. Drug susceptibility patterns of A.baumannii isolated





Cotrimoxazole (%) 22 (81.5) 5 (18.5) 0 (0)
Ciprofloxacin (%) 17 (70.8) 6 (25) 1 (4.2)
Ceftazidime (%) 13 (68.4) 4 (21) 2 (10.5)
Cefepime (%) 11 (61.1) 6 (33.3) 1 (5.6)
Tobramycin (%) 8 (47) 7 (41.2) 2 (11.8)
Gentamycin (%) 23 (85.2) 3 (11.1) 1 (3.7)
Amikacin (%) 17 (85) 3 (15) 0 (0)
Pipericillin-tazobactam (%) 107 (89.9) 9 (7.6) 3 (2.5)
Meropenem (%) 224 (89.2) 25 (10.0) 2 (0.8)
Colistin (%) 2 (2.7) 71 (97.3) 0 (0)
Colistin MIC, mean (range) 3.25 (2.5–6) 0.6 (0.064–4) –
MIC=minimum inhibitory concentration.
doi:10.1371/journal.pone.0052452.t003
Acinetobacter baumannii Infection in HIV
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above this threshold) were the occurrence of MAEs in ICU
(p= 0.023), development of MODS (p= 0.041) and an APACHE
II score greater than 30 (p = 0.001). The conclusions of this
analysis did not change significantly when the analysis was
confined to those with infection only vs. colonisation/infection.
Discussion
To our knowledge this is the first detailed report describing
A.baumannii epidemiology and outcomes from a resource-poor,
high HIV prevalence setting. The key findings of our study were
that ICU-associated A.baumannii infection in this setting: (i) occurs
frequently; (ii) has a high in-ICU mortality; (iii) is frequently
multidrug-resistant but remains largely susceptible to colistin; (iv)
has a predilection for the respiratory tract and bloodstream, and
often occurs in conjunction with ventilator-associated pneumonia,
and (v) death in patients with A.baumannii infection is associated
with several parameters including older age, low CD4 count if
HIV positive, surgery during admission, co-morbid Gram negative
sepsis, a high APACHE II score, and a positive blood culture for
A.baumannii. Importantly, this is the first study to show that in those
with ICU-related A.baumannii infection advanced HIV infection
was associated with higher mortality. Our results have implications
for resource allocation and management of patients with
A.baumannii colonisation/infection in resource-poor settings, and
highlight the need for aggressive treatment of patients with
a positive blood culture, who are older, have a low CD4 count in
the context of HIV-infection, high APACHE II scores at
admission, or those with evidence of MODS.
The incidence and prevalence of A.baumannii infection is on the
rise in Western nations. [14–17] By contrast, although thought to
be an uncommon pathogen in an African setting, we show here
that A.baumannii colonisation/infection is common in a South
African ICU with an incidence of 15 per 100 person-years.
Mortality was also high at 26.5 per 100 person-years. The
mortality is similar to that reported by Trottier et al of 26.2% in
critically ill American patients. [18] Other reports have demon-
strated a mortality rate of 8–43% due to A.baumannii in Western
countries [19–21] and of 33–45% in developing countries outside
Africa, however, several of these studies did not control for
confounding risk factors including age, disease severity, co-
morbidity etc. [22,23] We found a similar incidence and mortality
rate to resource rich countries, where control of A.baumannii
remains a significant challenge. Thus, solutions to the challenge of
managing A.baumannii are likely to transcend resource and
economic boundaries, and should include strict attention to
infection control, stringent antibiotic stewardship, molecular
fingerprinting to uncover transmission links, and development of
novel strategies including therapeutic immunisation against the
bacterium. [24] However, as Perez and colleagues note, ‘‘the
success of all of these approaches depends on the commitment of
clinical practitioners, scientists, hospital and public health admin-
istrators and on the support of an informed and concerned
public.’’ [24].
There are hardly any data about A.baumannii colonisation/
infection in HIV-infected persons and none from high HIV
Table 4. Multivariate logistical regression analysis of predictors of mortality in those with A.baumannii colonisation/infection.
Characteristic Multi-variate logistic regression analysis
Odds ratio (95% CI) P-value
Age 1.073 (1.010–1.140) 0.023
If HIV positive, CD4 count 1.698 (1.042–3.275) 0.038
Recent surgery in this admission 5.942 (1.026–34.413) 0.047
Co-morbid Gram negative sepsis 11.494 (1.639–80.580) 0.014
APACHE II score 123.941(5.483–1373.197) 0.001
MODS after A.baumannii infection 83.003 (6.873–739.037) 0.012
Blood culture positive for A.baumannii 13.158 (1.595–108.522) 0.017
HIV = human immunodeficiency virus, CD4 = cluster of differentiation 4, APACHE II = Acute Physiology and Chronic Health Evaluation II, MODS=multi-organ dysfunction
syndrome.
doi:10.1371/journal.pone.0052452.t004
Table 5. Multivariate logistical regression analysis of features
predictive for Acinetobacter infection in HIV-infected persons




Odds ratio (95% CI) P-value
Younger age 1.206 (1.013–1.638) 0.042
Female gender 1.607 (1.230–2.998) 0.028
CD4 count ,200 cells/ml 3.878 (1.475–12.943) 0.037
Elevated APACHE II score (.30) 7.232 (1.567–18.479) 0.010
MODS after A.baumannii infection 9.573 (3.265–113.672) 0.032
doi:10.1371/journal.pone.0052452.t005
Table 6. Multivariate logistical regression analysis of
predictors of mortality in HIV-infected persons with





Odds ratio (95% CI) P-value
MODS after A.baumannii infection 13.001 (2.763–57.984) 0.041
APACHE II score (.30) 21.073 (6.839–137.852) 0.001
doi:10.1371/journal.pone.0052452.t006
Acinetobacter baumannii Infection in HIV
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prevalent settings like Africa. In a series of 10 patients, described
over a 9-year period in Italy, advanced immunosuppression was
associated with septicaemia. [22] While immunosuppression in
general has been shown to be a significant risk factor for mortality
from A.baumannii infection, [25] two studies with small numbers of
HIV-infected patients have concluded that HIV infection does not
predict poor outcomes from A.baumannii infection, as AIDS in
these studies showed good outcome with adequate treatment.
[18,25] By contrast, we observed that HIV with clinical AIDS was
associated with higher overall mortality and within the HIV-
infected subgroup those with AIDS are more likely to have
a positive blood culture. Moreover, compared to HIV-infected
patients with preserved immunity, AIDS patients who died in the
ICU were also younger, more likely to be female, sicker (higher
APACHE II scores), and had more frequent MAEs and MODS.
In contradistinction with our findings, multivariate logistical
regression analysis from the large, multi-centre and multi-national
EPIC II study showed that HIV infection was independently
associated with a higher risk of A.baumannii infection, but not with
increased mortality. [12] Our findings thus have implications for
the management of HIV-infected patients with A.baumannii
infection (signs of sepsis or a positive blood culture) and now
need confirmation in larger prospective studies. First, it is
important to treat Acinetobacter bacteraemia early with antibiotics.
Second, HIV infected patients and in particular those with low
immunity, are at increased risk of A.baumannii infection and
mortality, and hence need to be treated aggressively in order to
avert poor outcomes. Third, more research and resources are
needed in order to develop and implement preventative strategies
for A.baumannii infection, especially in those who are immuno-
compromised.
Risk factors for A.baumannii colonisation in this high HIV-
prevalence setting included prior ICU admission, invasive
ventilation in ICU, admission to the trauma unit before ICU
admission and ETT insertion in the trauma unit. These data
suggest that the trauma unit and ICUs themselves are likely
reservoirs facilitating transmission, and targeted surveillance and
eradication may be required in these areas. Nevertheless, although
admission via the trauma unit was an important risk factor for
colonisation, this group had minimal mortality presumably
because they were young and with little co-morbidity. It is likely
that A.baumannii in this study was largely nosocomially acquired as
it was cultured in the second week of hospital admission in almost
all patients and had a high intrinsic resistance to most broad-
spectrum antibiotics.
This study had several limitations, including the inherent
drawbacks of a retrospective design, variable dosing and duration
of antibiotic therapy, simultaneous administration of other
antibiotics, and lack of monitoring of resistance patterns before
and after therapy. Physician bias in initiating antibiotic treatment
(and hence subjective definition of colonisation) is a drawback that
we are unable to address because of study design, however, our
study conclusions did not change when the analysis was performed
using those with infection rather than colonisation/infection.
Moreover, it is likely that the physician-based classification has
reasonable credibility given that there were no deaths in the
colonisation group. A second major limitation of our study is the
lack of a matched control population who did not have
Acinetobacter colonisation/infection and thus we are unable to
determine to what extent death was due to Acinetobacter rather
than other co-morbidities. Nevertheless, mortality (26%) was
higher than that generally found in the ICU (,15%) and we were
able to address our primary aim – to provide a preliminary
description of the epidemiology, clinical profile and risk factors
associated with mortality in HIV-infected compared to HIV
uninfected persons in this resource-poor high HIV prevalence
setting. Seventeen (6.3%) of the patients admitted to ICU with
A.baumannii colonisation/infection during the study period either
had missing files or incomplete information; however, a sensitivity
analysis showed that this group was similar to those patients
included in the study. Whether HIV per se is a risk factor for
A.baumannii colonisation/infection cannot be determined within
the current study design and will be addressed in a prospective
study, which is now required in different African centres to
confirm our findings.
In conclusion, our data show that A.baumannii colonisation/
infection is frequent in critically ill patients admitted to ICUs in
Cape Town, South Africa, and is associated with significant risk of
death. Amongst those with A.baumannii colonisation/infection
HIV-infection with clinical AIDS is associated with high mortality
and A.baumannii-specific septicaemia. Collectively these data,
including the description of risk factors for colonisation and
mortality in HIV-infected and uninfected patients in the ICU, will
likely facilitate the rational allocation of resources and implemen-
tation of targeted interventions to prevent and treat A.baumannii in
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